TITLE

Licensure of a Haemophilus influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for Use of Hib Vaccine

PUB. DATE
September 2009
SOURCE
MMWR: Morbidity & Mortality Weekly Report;9/18/2009, Vol. 58 Issue 36, p1008
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses how Hiberix was licensed by the U.S. Food and Drug Administration (FDA) on August 19, 2009. Hiberix is a Haemophilus influenzae type b (Hib) vaccine and can be used as a booster dose for at least 15 month old babies to four year old children who have received their Hib primary series vaccines. The study conducted by the FDA involved giving Hib vaccines along with tetanus and acellular pertussis vaccines. The availability of Sanofi Pasteur vaccines is also presented.
ACCESSION #
44303289

 

Related Articles

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Aug2008, Vol. 27 Issue 11, p2 

    The article reports on the actions made by the U.S. Food and Drug Administration (FDA). The agency has approved a new pentavalent vaccine for 6-week to 4-year-old children which is being marketed by Sanofi Pasteur and combines diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus...

  • Conjugate vaccine approved by FDA, ACIP adds vaccine to Vaccines for Children.  // Infectious Disease News;Jul2008, Vol. 21 Issue 7, p21 

    The article reports that the U.S. Food & Drug Administration has licensed the diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate vaccine Pentacel manufactured by Sanofi Pasteur. The vaccine is approved for use in infants and...

  • Four different H1N1 vaccines approved.  // Contemporary Pediatrics;Oct2009, Vol. 26 Issue 10, p16 

    The article reports that four pharmaceutical companies have been given approval by the Food and Drug Administration (FDA) in the U.S. for their H1N1 influenza vaccines. All these companies, sanofi pasteur, MedImmune, CSL Ltd. and Novartis Vaccines and Diagnostics, have previous experiences with...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Aug2008 Pharmacology Watch, p2 

    The article focuses on recent actions by the U.S. Food and Drug Administration (FDA) as of August 2008. The FDA approved a new pentavalent vaccine for children age 6 weeks through 4 years that combines diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenza type b. 23 U.S....

  • FDA APPROVES COMBINATION HIB, MENINGOCOCCAL DISEASE VACCINE.  // Contemporary Pediatrics;Jul2012, Vol. 29 Issue 7, p10 

    The article discusses the approval of a combination vaccine for preventing invasive diseases caused by the bacteria Haemophilus influenza type b (Hib) and Neisseria meningitidis serogroups C and Y (meningococcal disease) in children aged 6 weeks to 18 months by the FDA.

  • Sanofi Warned for Vaccine Facilities.  // BioWorld Today;7/26/2012, Vol. 23 Issue 144, p5 

    The article reports that the U.S. Food and Drug Administration (FDA) has summoned senior Sanofi Pasteur officials to discuss manufacturing problems at the company's vaccine facilities in Toronto, Ontario and Marcy L'etoile, France.

  • Menactra: Now serving ages 2 to 10.  // Contemporary Pediatrics;Nov2007, Vol. 24 Issue 11, p16 

    The article reports that the U.S. Food and Drug Administration (FDA) has expanded the approved age range for the bacterial meningitis vaccine, Menactra, to include children 2 to 10 years of age. Menactra, manufactured by sanofi pasteur, reportedly was first sanctioned in 2005 for patients, ages...

  • Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, and Haemophilus b Conjugate Vaccine and Guidance for Use in Infants and Children.  // MMWR: Morbidity & Mortality Weekly Report;10/3/2008, Vol. 57 Issue 39, p1079 

    The article details the authorization granted by the U.S. Food and Drug Administration on the use of Pentacel, a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus influenza type b conjugate toxoid vaccine. This report also reviews the...

  • FDA gives nod to vaccine plant in U.S.  // Medical Device Daily;5/11/2009, Vol. 13 Issue 89, p3 

    The article reports on the decision of the U.S. Food and Drug Administration(FDA) to allow the construction of a vaccine manufacturing plant by Sanofi Pasteur in Swiftwater, Pennsylvania. According to Jesse Goodman, deputy commissioner for scientific and medical programs at FDA, the plant will...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics